title: Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-HT1A receptor, in the prefrontal cortex of subjects with major depression.
abstract: Serotonin1A (5-HT(1A)) receptors are reported altered in the brain of subjects with major depressive disorder (MDD). Recent studies have identified transcriptional regulators of the 5-HT(1A) receptor and have documented gender-specific alterations in 5-HT(1A) transcription factor and 5-HT(1A) receptors in female MDD subjects. The 5' repressor element under dual repression binding protein-1 (Freud-1) is a calcium-regulated repressor that negatively regulates the 5-HT(1A) receptor gene. This study documented the cellular expression of Freud-1 in the human prefrontal cortex (PFC) and quantified Freud-1 protein in the PFC of MDD and control subjects as well as in the PFC of rhesus monkeys chronically treated with fluoxetine. Freud-1 immunoreactivity was present in neurons and glia and was co-localized with 5-HT(1A) receptors. Freud-1 protein level was significantly decreased in the PFC of male MDD subjects (37%, p=0.02) relative to gender-matched control subjects. Freud-1 protein was also reduced in the PFC of female MDD subjects (36%, p=0.18) but was not statistically significant. When the data was combined across genders and analysed by age, the decrease in Freud-1 protein level was greater in the younger MDD subjects (48%, p=0.01) relative to age-matched controls as opposed to older depressed subjects. Similarly, 5-HT(1A) receptor protein was significantly reduced in the PFC of the younger MDD subjects (48%, p=0.01) relative to age-matched controls. Adult male rhesus monkeys administered fluoxetine daily for 39 wk revealed no significant change in cortical Freud-1 or 5-HT(1A) receptor proteins compared to vehicle-treated control monkeys. Reduced protein expression of Freud-1 in MDD subjects may reflect dysregulation of this transcription factor, which may contribute to the altered regulation of 5-HT(1A) receptors observed in subjects with MDD. These data may also suggest that reductions in Freud-1 protein expression in the PFC may be associated with early onset of MDD.
authors.affiliation: Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA.
authors.forename: Bernadeta
authors.initials: B
authors.lastname: Szewczyk
authors.forename: Paul R
authors.initials: PR
authors.lastname: Albert
authors.forename: Anastasia
authors.initials: A
authors.lastname: Rogaeva
authors.forename: Heidi
authors.initials: H
authors.lastname: Fitzgibbon
authors.forename: Warren L
authors.initials: WL
authors.lastname: May
authors.forename: Grazyna
authors.initials: G
authors.lastname: Rajkowska
authors.forename: Jose J
authors.initials: JJ
authors.lastname: Miguel-Hidalgo
authors.forename: Craig A
authors.initials: CA
authors.lastname: Stockmeier
authors.forename: William L
authors.initials: WL
authors.lastname: Woolverton
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Kyle
authors.forename: Zhixia
authors.initials: Z
authors.lastname: Wang
authors.forename: Mark C
authors.initials: MC
authors.lastname: Austin
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D003865:Major Depressive Disorder / Q000378:metabolism* / Q000523:psychology; D015536:Down-Regulation / Q000235:genetics / Q000502:physiology*; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000378:metabolism*; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics / Q000378:metabolism*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: C512283:CC2D1A protein, human; D004268:DNA-Binding Proteins; D044282:Receptor, Serotonin, 5-HT1A
references.citation: J Neurosci. 2003 Sep 24;23(25):8788-99
references.pmid: 14507979
references.citation: Neuropsychopharmacology. 1991 Feb;4(2):131-44
references.pmid: 2025379
references.citation: J Affect Disord. 1997 Feb;42(2-3):199-207
references.pmid: 9105961
references.citation: Cereb Cortex. 2002 Apr;12(4):386-94
references.pmid: 11884354
references.citation: Neuropsychopharmacology. 1997 Feb;16(2):162-73
references.pmid: 9015799
references.citation: Biol Psychiatry. 1999 May 1;45(9):1085-98
references.pmid: 10331101
references.citation: J Neurosci. 2006 Feb 8;26(6):1864-71
references.pmid: 16467535
references.citation: J Neurochem. 2003 Oct;87(1):182-94
references.pmid: 12969265
references.citation: CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33
references.pmid: 17511618
references.citation: Brain Res. 1995 Aug 7;688(1-2):121-33
references.pmid: 8542298
references.citation: Prog Neurobiol. 2009 May;88(1):17-31
references.pmid: 19428959
references.citation: Neuroscience. 2009 Nov 10;163(4):1119-27
references.pmid: 19647046
references.citation: Biol Psychiatry. 2004 Feb 1;55(3):225-33
references.pmid: 14744462
references.citation: Biol Psychiatry. 1994 Apr 1;35(7):457-63
references.pmid: 8018797
references.citation: Biol Psychiatry. 1999 Nov 15;46(10):1375-87
references.pmid: 10578452
references.citation: J Neurosci. 2003 Aug 13;23(19):7415-25
references.pmid: 12917378
references.citation: Fertil Steril. 2008 Mar;89(3):685-92
references.pmid: 17543959
references.citation: Int J Neuropsychopharmacol. 2009 Mar;12(2):155-68
references.pmid: 18561871
references.citation: Nucl Med Biol. 2007 Oct;34(7):865-77
references.pmid: 17921037
references.citation: J Biol Chem. 2007 Jul 20;282(29):20897-905
references.pmid: 17535813
references.citation: Cereb Cortex. 1995 Jul-Aug;5(4):307-22
references.pmid: 7580124
references.citation: Brain Res. 1991 Jul 19;554(1-2):56-64
references.pmid: 1834306
references.citation: Biol Psychiatry. 2004 Nov 1;56(9):640-50
references.pmid: 15522247
references.citation: Int J Neuropsychopharmacol. 2008 Jun;11(4):465-76
references.pmid: 17971260
references.citation: Brain Res Dev Brain Res. 2005 Jun 9;157(1):42-57
references.pmid: 15939084
references.citation: Neuropsychopharmacology. 2002 May;26(5):565-73
references.pmid: 11927181
references.citation: J Psychiatr Res. 2003 Sep-Oct;37(5):357-73
references.pmid: 12849929
references.citation: Neuropharmacology. 2000;39(1):110-22
references.pmid: 10665824
references.citation: Neuroscientist. 2004 Dec;10(6):575-93
references.pmid: 15534042
references.citation: Arch Gen Psychiatry. 2000 Feb;57(2):174-80
references.pmid: 10665620
references.citation: J Comp Neurol. 2001 May 7;433(3):390-400
references.pmid: 11298363
references.citation: Mol Psychiatry. 2004 Apr;9(4):386-92
references.pmid: 15042104
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2088-96
references.pmid: 15238995
references.citation: Eur J Neurosci. 2007 Aug;26(4):965-74
references.pmid: 17714190
references.citation: Biol Psychiatry. 2000 Oct 15;48(8):861-73
references.pmid: 11063981
references.citation: Nucl Med Biol. 2000 Jul;27(5):499-507
references.pmid: 10962258
references.citation: Neuropsychopharmacology. 2007 Feb;32(2):471-82
references.pmid: 17063153
references.citation: Biol Psychiatry. 2005 Aug 15;58(4):297-306
references.pmid: 15953590
references.citation: J Psychiatr Res. 2009 Jul;43(10):887-94
references.pmid: 19215942
references.citation: Semin Clin Neuropsychiatry. 2002 Oct;7(4):281-92
references.pmid: 12382210
references.citation: J Neural Transm Gen Sect. 1991;85(3):181-94
references.pmid: 1834090